A Little Funding for Pharmasset

It wasn't the biggest call for cash in the specialty pharma sector, but development-stage drugmaker Pharmasset (Nasdaq: VRUS  ) raised $10 million via a debt financing on Friday.

Shares of Pharmasset have been on fire since its potential hepatitis C-fighting antiviral compound produced strong phase 1 clinical trial results in January. Like all money-losing drugmakers without a compound on the market, Pharmasset needs to raise cash to continue developing its pipeline of other hepatitis and anti-HIV compounds.

The loan Pharmasset received Friday was the second $10 million of a three-part loan agreement for up to $30 million that it signed last year. With the new funds on its balance sheet, in addition to $63 million that it had at the end of 2007, Pharmasset said its cash will last another 18 months.

Pharmasset is competing against other drugmakers like Schering-Plough (NYSE: SGP  ) and Wyeth (NYSE: WYE  ) in trying to develop the first antiviral hepatitis C compound. Its hepatitis C polymerase inhibitor, which it's developing with Roche, is set to begin phase 2b testing in the fourth quarter, if all goes according to plan.

How a development-stage drugmaker handles its cash-and-burn rate can be a bellwether about what sort of steward it will be with shareholder cash if its drugs ever do get approved and the money starts flowing. This is why investors should always follow how wisely a development-stage drugmaker uses its cash.

After all, finding a drugmaker with a valuable pipeline is only half the battle. Making sure it takes advantage of its assets without overspending is just as important, as can be seen when a drugmaker squanders its funding and paints itself into a corner.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 610372, ~/Articles/ArticleHandler.aspx, 9/22/2014 8:36:39 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement